Lexeo Therapeutics Jumps 12.5% on Positive Interim Heart-Disease Gene Therapy Data

The company also reported third-quarter results and said the FDA is open to using non-sustained ventricular tachycardia as a primary endpoint for a pivotal study.

Covid 19 coronavirus vaccine vial bottle for intramuscular injections on medical pharmaceutical industry background. Corona v
Photo: Ground Picture/Shutterstock.com

Key points

  • Lexeo rose 12.5% on Monday, Nov. 16, 2026 after positive interim LX2020 data in PKP2 arrhythmogenic cardiomyopathy
  • High-dose cohorts showed an 80% mean NSVT reduction and a 44% mean PVC reduction at latest assessment
  • FDA is open to NSVT as a primary surrogate endpoint for a pivotal study
  • Cash and investments together of $219.1 million are expected to fund operations into 2028

Lexeo Therapeutics (Nasdaq: LXEO) rose 12.5% on Monday, Nov. 16, 2026, closing at $3.23 against a previous close of $2.87, while the S&P 500 ETF (SPY) fell 1.91% that session. Trading volume was about 31.7 times its usual level.

The move followed an 8-K filed before the market opened, which included a press release announcing positive interim Phase I/II data for LX2020 in PKP2 arrhythmogenic cardiomyopathy and the company's third-quarter 2026 financial results.

Arrhythmia reductions in high-dose cohorts

In the high-dose cohorts (n=7), the company reported an 80% mean reduction in non-sustained ventricular tachycardia (NSVT) and a 44% mean reduction in premature ventricular contractions at the latest assessment, relative to baseline. Ten participants have been dosed, and the company said LX2020 was generally well tolerated with no clinically significant complement activation.

A possible path to accelerated approval

The company said the U.S. Food and Drug Administration is open to guideline-defined NSVT as a primary surrogate endpoint to support potential accelerated approval. Lexeo said finalization of the pivotal study design is expected in the first half of 2027, with initiation anticipated in the second half of 2027. The company noted the final design remains subject to future FDA discussions.

Cash runway

Lexeo reported cash, cash equivalents and investments of $219.1 million, which it expects to provide operational runway into 2028. The company's 10-Q, filed with the 8-K, reported a net loss of $38.3 million for the third quarter, compared with $20.3 million a year earlier.

The filings do not state a specific reason for the stock's move on the day beyond the data and regulatory update described above.

Sources

Written with AI from SEC filings and market data, and checked against those sources before publishing. Our editorial standards.

Other stock movers this week

Latest earnings results →
LXEO page →

Filings, figures and price history are on the Lexeo Therapeutics page.